Specificity of Pharmacological and Toxicological Studies on Juvenile Animals
DOI:
https://doi.org/10.20535/ibb.2026.10.1.354861Keywords:
juvenile animals’ studies, ontogenesis stages, choice of animal species, safety, drug effects, pediatric populationAbstract
Abstract. With levels of medicine and pharmacology individualization constantly increasing, the scientific community is becoming seriously concerned about the safety of existing and developing drugs for the pediatric population insufficient assessment. The aim of this review is to analyze the main problems arising in the development and preclinical evaluation of drugs for children and adolescents, taking into account their age-related physiological and biochemical characteristics, as well as the selection of adequate juvenile experimental models among various animal species.
Juvenile animal studies planning should be based on the specific age group of the pediatric population for which a specific drug is being developed. They cannot be conducted using standardized research protocols and require an individual approach in each specific case. Their design should include the study of drug effects at all ontogenesis stages, without exception, that correspond to the growth and development of the relevant pediatric population. Also fundamental are the correct choice of animal species, based on its sensitivity to the effects of the drug, the availability of relevant data from preclinical studies on adult animals and the planned procedures and types of studies, some of which can only be carried out on certain animal species. Pathologists should be able to compare tissue structures in parallel in an experiment, both normal and drug-treated, at all stages of ontogenesis, and have access to as many reference and image databases as possible. All of the above requirements are the minimum to ensure adequate support for clinical trials in the pediatric population.
References
Janczura M, Sip S, & Cielecka-Piontek J. The Development of Innovative Dosage Forms of the Fixed-Dose Combination of Active Pharmaceutical Ingredients. Pharmaceutics, 2022; 14(4): 834. DOI: 10.3390/pharmaceutics14040834
Galkin OYu, Lutsenko TM, Gorshunov YuY, Motronenko VV. Development of the method for microbiological purity testing of recombinant human interleukin-7-based product. The Ukrainian Biochemical Journal, 2014; 89(3):52-59. DOI: 10.15407/ubj89.03.052
Volodina TT, Korotkevich NV, Romaniuk SI, Galkin OYu, Kolybo DV, Komisarenko SV. Implementation of Dietary Supplements with Effect of Dezintoxication and Improvement of Osteogenesis and Metabolism. Science and Innovation, 2017; 13(6): 39-50. DOI: 10.15407/scine13.06.039
Turner MA, Cheng K, de Wildt S, Hildebrand H, Attar S, Rossi P, Bonifazi D, Ceci A, Claverol J, Nafria B, & Giaquinto C. European research networks to facilitate drug research in children. British Journal of Clinical Pharmacology, 2022; 88(10): 4258–4266. DOI: 10.1111/bcp.14545
Department of Health and Human Services (US); Food and Drug Administration (FDA); Center for Drug Evaluation and Research (CDER). Nonclinical Safety Evaluation of Pediatric Drug Products; Pharmacology and Toxicology, Office of Training and Communications, Division of Drug Information: Rockville, MD, USA, 2006. https://www.fda.gov/media/119658/download
European Medicines Agency (EMA). Paediatric Committee (PDCO)—Guideline on Pharmaceutical Development of Medicines for Paediatric Use; EMEA: London, UK, 2014. https://www.ema.europa.eu/en/pharmaceutical-development-medicines-paediatric-use-scientific-guideline
Tavares D, Chien H-T, Sheean ME, Theunissen P, van Meer P and Van Malderen K. From guideline to practice: three years of ICH S11 insights and recommendations. Front. Med. 2025; 12:1537001. DOI: 10.3389/fmed.2025.1537001
Halpern SA. American pediatrics: the social dynamic of professionalism, 1880–1980. Berkeley: University of California Press, 1988:52.
Drug dosage in children. In: Ritschel WA. Handbook of basic pharmacokinetics. 2nd ed. Hamilton, Ill.: Drug Intelligence, 1980:296-310.
Rao D.B. , Hoberman A.M., Brown P.C. , Varela A., Bolon B. Regulatory Perspectives on Juvenile Animal Toxicologic Pathology. Toxicologic Pathology. 2021; 49(8):1303-1404 DOI: 10.1177/01926233211046869
Baldrick P. Juvenile animal studies in human drug development. Expert opinion on pharmacotherapy.2025; 26, no. 3, 227–229. DOI: 10.1080/14656566.2025.2456589
Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol. 2000; 106: Suppl:S128-S138. DOI: 10.1067/mai.2000.109419.
Agunod M, Yamaguchi N, Lopez R, Luhby AL, Glass GB. Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis. 1969;14:400-414. DOI: 10.1007/BF02239360
Rodbro P, Krasilnikoff PA, Christiansen PM. Parietal cell secretory function in early childhood. Scand J Gastroenterol. 1967;2: 209-213. DOI: 10.3109/00365526709180071
Huang NN, High RH. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr 1953;42:657-68. DOI: 10.1016/s0022-3476(53)80422-1.
Suchy FJ, Balistreri WF, Heubi JE, Searcy JE, Levin RS. Physiologic cholestasis: elevation of the primary serum bile acid concentrations in normal infants. Gastroenterology. 1981;80:1037-1041. DOI: 10.1016/0016-5085(81)90078-0
Poley JR, Dower JC, Owen CA Jr, Stickler GB. Bile acids in infants and children. J Lab Clin Med .1964;63:838-846. PMID: 14158066
Heimann G. Enteral absorption and bioavailability in children in relation to age. Eur J Clin Pharmacol. 1980;18:43-50. DOI: 10.1007/BF00561477.
Weaver LT, Austin S, Cole TJ. Small intestinal length: a factor essential for gut adaptation. Gut. 1991;32:1321-1323. DOI: 10.1136/gut.32.11.1321.
Yanowitz TD, Yao AC, Pettigrew KD, Werner JC, Oh W, Stonestreet BS. Postnatal hemodynamic changes in very-low-birthweight infants. J Appl Physiol. 1999;87:370-380. DOI: 10.1152/jappl.1999.87.1.370.
Martinussen M, Brubakk AM, Vik T, Yao AC. Mesenteric blood flow velocity and its relation to transitional circulatory adaptation in appropriate for gestational age preterm infants. Pediatr Res. 1996;39:275-280. DOI: 10.1203/00006450-199602000-00015.
Martinussen M, Brubakk AM, Linker DT, Vik T, Yao AC. Mesenteric blood flow velocity and its relation to circulatory adaptation during the first week of life in healthy term infants. Pediatr Res. 1994;36:334-339. DOI: 10.1203/00006450-199409000-00011.
Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos. 1999;27:161-166. DOI: 10.1016/S0090-9556(24)15271-3
Stahlberg MR, Hietanen E, Maki M. Mucosal biotransformation rates in the small intestine of children. Gut. 1988;29:1058-1063. DOI: 10.1136/gut.29.8.1058.
Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos. 1999;27:1466-1469. DOI: 10.1016/S0090-9556(24)14957-4
Linday L, Dobkin JF, Wang TC, Butler VP Jr, Saha JR, Lindenbaum J. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics. 1987;79:544-548. PMID: 3822671 DOI: 10.1542/peds.79.4.544
Rutter N. Percutaneous drug absorption in the newborn: hazards and uses. Clin Perinatol. 1987;14:911-930. PMID: 3322630 DOI: 10.1016/s0095-5108(18)30740-1
Okah FA, Wickett RR, Pickens WL,Hoath SB. Surface electrical capacitance as a noninvasive bedside measure of epidermal barrier maturation in the newborn infant. Pediatrics. 1995;96:688-692. PMID: 7567331 DOI: 10.1542/peds.96.4.688
Fluhr JW, Pfisterer S, Gloor M. Direct comparison of skin physiology in children and adults with bioengineering methods. Pediatr Dermatol. 2000;17:436-439. DOI: 10.1046/j.1525-1470.2000.01815.x.
Amato M, Huppi P, Isenschmid M, Schneider H. Developmental aspects of percutaneous caffeine absorption in premature infants. Am J Perinatol. 1992;9:431-434. DOI: 10.1055/s-2007-999282.
West DP, Worobec S, Solomon LM. Pharmacology and toxicology of infant skin. J Invest Dermatol. 1981;76:147-150. DOI: 10.1111/1523-1747.ep12525553.
Friis-Hansen B. Water distribution in the foetus and newborn infant. Acta Paediatr Scand. Suppl 1983;305:7-11. DOI: 10.1111/j.1651-2227.1983.tb09852.x.
Siber GR, Echeverria P, Smith AL, Paisley JW, Smith DH. Pharmacokinetics of gentamicin in children and adults. J Infect Dis. 1975;132:637-651. DOI: 10.1093/infdis/132.6.637.
Windorfer A, Kuenzer W, Urbanek R. The influence of age on the activity of acetylsalicylic acid-esterase and protein-salicylate binding. Eur J Clin Pharmacol. 1974;7:227-231. DOI: 10.1007/BF00560385.
Ehrnebo M, Agurell S, Jalling B, Boreus LO. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur J Clin Pharmacol. 1971;3:189-193. DOI: 10.1007/BF00565004
Fredholm BB, Rane A, Persson B. Diphenylhydantoin binding to proteins in plasma and its dependence on free fatty acid and bilirubin concentration in dogs and newborn infants. Pediatr Res. 1975;9:26-30. DOI: 10.1203/00006450-197501000-00005
Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42:59-98. DOI: 10.2165/00003088-200342010-00003.
Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther. 2002;300:355-360. DOI: 10.1124/jpet.300.2.355
McCarver DG, Hines RN. The ontogeny of human drug metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther. 2002; 300:361-366. DOI: 10.1124/jpet.300.2.361
Young WS, Lietman PS. Chloramphenicol glucuronyl transferase: assay, ontogeny and inducibility. J Pharmacol Exp Ther. 1978; 204:203-211. PMID: 412948 DOI: 10.1016/s0022-3565(25)31127-4
Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant: a physiologic explanation of its toxicity when given in excessive doses. N Engl J Med. 1960; 262:787-794. doi: 10.1056/NEJM196004212621601.
Arant BS Jr. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr. 1978;92:705-712. DOI: 10.1016/s0022-3476(78)80133-4.
van den Anker JN, Schoemaker RC, Hop WC, et al. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther. 1995;58:650-659. DOI: 10.1016/0009-9236(95)90021-7.
James LP, Marotti T, Stowe CD, Farrar HC, Taylor BJ, Kearns GL. Pharmacokinetics and pharmacodynamics of famotidine in infants. J Clin Pharmacol. 1998;38:1089-1095. PMID: 11301560 DOI: 10.1177/009127009803801202
Brion LP, Fleischman AR, Schwartz GJ. Gentamicin interval in newborn infants as determined by renal function and postconceptional age. Pediatr Nephrol. 1991;5:675-679. DOI: 10.1007/BF00857868.
Szefler SJ, Wynn RJ, Clarke DF, Buckwald S, Shen D, Schentag JJ. Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. J Pediatr. 1980;97:312-315. DOI: 10.1016/s0022-3476(80)80506-3.
van den Anker JN, Hop WC, de Groot R, et al. Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr Res. 1994;36:578-581. DOI: 10.1203/00006450-199411000-00006.
Takahashi H, Ishikawa S, Nomoto S, et al. Developmental changes in pharmacokineticsand pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther. 2000;68:541-555. DOI: 10.1067/mcp.2000.110977.
Marshall JD, Kearns GL. Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther. 1999;66:66-75. DOI: 10.1016/S0009-9236(99)70055-X.
Marshall J, Rodarte A, Blumer J, Khoo K-C, Akbari B, Kearns GL. Pediatric pharmacodynamics of midazolam oral syrup. J Clin Pharmacol. 2000;40:578-589. PMID: 10868308 DOI: 10.1002/j.1552-4604.2000.tb05983.x
deWildt SN, Kearns GL, Sie SD, Hop WCJ, van den Anker JN. Pharmacodynamics of intravenous and oral midazolam in preterm infants. Clin Drug Invest. 2003;23:27-38. DOI: 10.2165/00044011-200323010-00004.
Silverman ES, Liggett SB, Gelfand EW, et al. The pharmacogenetics of asthma: a candidate gene approach. Pharmacogenomics J. 2001;1:27-37. DOI: 10.1038/sj.tpj.6500005.
Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia — current status and future perspectives. Lancet Oncol. 2001;2:597-607. DOI: 10.1016/S1470-2045(01)00516-2
Leeder JS. Ontogeny of drug-metabolizing enzymes and its influence on the pathogenesis of adverse drug reactions in children. Curr Ther Res. 2001;62:900-912. DOI: 10.1007/978-1-0716-1554-6_18.
Jadcherla SR, Berseth CL. Effect of erythromycin on gastroduodenal contractile activity in developing neonates. J Pediatr Gastroenterol Nutr. 2002;34:16-22. DOI: 10.1097/00005176-200201000-00005.
Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants. Clin Pharmacokinet. 2002;41:1077-1094. DOI: 10.2165/00003088-200241130-00005.
Hurtt MA, Engel S. An update of juvenile animal studies in the European Union: what do the numbers say? Reprod Toxicol. 2015;56:105-108. DOI: 10.1016/j.reprotox.2015.04.011. Epub 2015 Apr 30.
Bailey G, Marien D. The value of juvenile animal studies “What have we learned from preclinical juvenile toxicity studies? II”. Birth Defects Res. Part B. Dev Reprod Toxicol. 2011;92:273-291. DOI: 10.1002/bdrb.20328
Barrow PC, Barbellion S, Stadler J. Preclinical evaluation of juvenile toxicity. Methods Mol Biol. 2011;691:17-35. DOI: 10.1007/978-1-60761-849-2_2.
Kaufman RE. Drug therapeutics in the infant and child. In: Yaffe SJ,Aranda JV, eds. Pediatric Pharmacology: Therapeutic Principles in Practice. Washington, DC: Saunders Company; 1992:212-219.
Parker RM. Juvenile toxicology. In: Derelanko M, Auletta C, eds. Handbook of Toxicology. 3rd Edition. Boca Raton, FL: CRC Press; 2014:399.
Buelke-Sam J. Comparative schedules of development in rats and humans: implications for developmental neurotoxicity testing. Toxicological Sciences. 2003; 72(Suppl 1): 169
Löscher W, Kaila K. CNS pharmacology of NKCC1 inhibitors. Neuropharmacology. 2022 Mar 1;205:108910. DOI: 10.1016/j.neuropharm.2021.108910. Epub 2021 Dec 6.
Kilborn S, Trudel G, Uhthoff H. Review of growth plate closure compared with age at sexual maturity and lifespan in laboratory animals. Contemp Top Lab Anim Sci. 2002;41(5):21-26. PMID: 12213043
Hoberman AM, Lewis EM, eds. Pediatric Non-Clinical Drug Testing: Principles, Requirements and Practices. Hoboken, New Jersey: John Wiley; 2011:339 p. DOI: 10.1002/9781118168226
Cappon GD, Bailey G P, Buschmann J, et al. Juvenile Animal Toxicity Study Designs to Support Pediatric Drug Development. Birth Defects Research (Part B). 2009; 86:463–469. DOI: 10.1002/bdrb.20220.
EMEA. 2008. European Medicines Agency (EMEA), Committee for Human Medicinal Products (CHMP). Guideline on the need for nonclinical testing in juvenile animals on human pharmaceuticals for paediatric indications. January 2008. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/multidisciplinary-guidelines/scientific-guidelines-paediatrics
FDA. 2006. United States Food and Drug Administration (FDA).Guidance document. Nonclinical safety evaluation of pediatric drug products. Silver Spring, MD: FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-evaluation-pediatric-drug-products
ICH. 2009. ICH M3 guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Geneva: ICH. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m3r2-non-clinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorisation-pharmaceuticals-step-5_en.pdf
Hurtt ME, Sandler JD. Comparative organ system development: introduction. Birth Defects Res B. Dev Reprod Toxicol. 2003 Apr;68(2):85. DOI: 10.1002/bdrb.10011.
Beckman DA, Feuston M. Landmarks in the development of the female reproductive system. Birth Defects Res B. Dev Reprod Toxicol. 2003;68:137–143. DOI: 10.1002/bdrb.10016.
Hew KW, Keller KA. Postnatal anatomical and functional development of the heart: a species comparison. Birth Defects Res B Dev Reprod Toxicol. 2003; 68:309–320. DOI: 10.1002/bdrb.10034.
Holsapple MP, West LJ, Landreth KS. Species comparison of anatomical and functional immune system development. Birth Defects Res B Dev Reprod Toxicol. 2003; 68:321–334. DOI: 10.1002/bdrb.10035.
Marty MS, Chapin RE, Parks LG, Thorsrud BA. Development and maturation of the male reproductive system. Birth Defects Res B Dev Reprod Toxicol. 2003; 68:125–136. DOI: 10.1002/bdrb.10015
Walthall K, Cappon GD, Hurtt ME, Zoetis T. Postnatal development of the gastrointestinal system: a species comparison. Birth Defects Res B Dev Reprod Toxicol 2005; 74:132–156. DOI: 10.1002/bdrb.20040
Watson RE, Desesso JM, Hurtt ME, Cappon GD. Postnatal growth and morphological development of the brain: a species comparison. Birth Defects Res B Dev Reprod Toxicol. 2006; 77:471–484. DOI: 10.1002/bdrb.20090
Wood SL, Beyer BK, Cappon GD. Species comparison of postnatal CNS development: functional measures. Birth Defects Res B Dev Reprod Toxicol. 2003; 68:391–407. DOI: 10.1002/bdrb.10037
Zoetis T, Hurtt ME. Species comparison of anatomical and functional renal development. Birth Defects Res B Dev Reprod Toxicol. 2003; 68:111–120. DOI: 10.1002/bdrb.10013
Zoetis T, Hurtt ME. Species comparison of lung development. Birth Defects Res B Dev Reprod Toxicol. 2003; 68:121–124. DOI: 10.1002/bdrb.10014
Zoetis T, Tassinari MS, Bagi C, Walthall K, Hurtt ME. Species comparison of postnatal bone growth and development. Birth Defects Res B Dev Reprod Toxicol. 2003; 68:86–110. DOI: 10.1002/bdrb.10012
Kim NN., Parker RM., Weinbauer GF., et al.Points to Consider in Designing and Conducting Juvenile Toxicology Studies. International Journal of Toxicology. 2017; 36(4): 325-339 DOI: 10.1177/1091581817699975
Seely JC. A brief review of kidney development, maturation, developmental abnormalities, and drug toxicity: juvenile animal relevancy. J Toxicol Pathol. 2017; 30: 125–133. DOI: 10.1293/tox.2017-0006
Schreuder MF, Bueters RR, Huigen MC, Russel FG, Masereeuw R, and van den Heuvel LP. Effect of drugs on renal development. Clin J Am Soc Nephrol. 2011; 6: 212–217. DOI: 10.2215/CJN.04740510
Whitney KM. Testicular histopathology in juvenile rat toxicity studies. Systems Biology in Reproductive Medicine. 2012; 58: 51–56. DOI: 10.3109/19396368.2011.647380
Stoker, T.E., Parks, L.G., Gray, L.E. and Cooper, R.L. Endocrine-disrupting chemicals: Prepubertal exposures and effects on sexual maturation and thyroid function in the male rat. A focus on the EDSTAC recommendations. Crit Rev Toxicol. 2000; 30:197–252. DOI: 10.1080/10408440091159194.
Wang Y, Yang XD, Chen ZQ, Hu C, Wang YB. Recent advances in the application of Injectable hydrogels for myocardial infarction. Biomed Eng Commun. 2025;4(4):25. DOI:10.53388/BMEC2025025
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The ownership of copyright remains with the Authors.
Authors may use their own material in other publications provided that the Journal is acknowledged as the original place of publication and National Technical University of Ukraine “Igor Sikorsky Kyiv Polytechnic Institute” as the Publisher.
Authors are reminded that it is their responsibility to comply with copyright laws. It is essential to ensure that no part of the text or illustrations have appeared or are due to appear in other publications, without prior permission from the copyright holder.
IBB articles are published under Creative Commons licence:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under CC BY 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
